1/4
Export Ready

FASTOGRAF 300 INJ

Sold by melizza lifescience · Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup · Rajkot, Gujarat, India

Price
Price on request
In stock
Inclusive of all taxes
Minimum order: 1 Centimetre

Export Snapshot

MOQ
1 Centimetre
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
As per product specification
HS Code
On request
Origin
India
Port of dispatch
On request
Export markets served
Algeria flag DZ Andorra flag AD Anguilla flag AI Angola flag AO Argentina flag AR +47 others
Values shown are for melizza lifescience.
Compliance & Certifications
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

melizza lifescience is a Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup based in Rajkot Gujarat India.

Rajkot Dispatch on request Verified seller
melizza lifescience logo

melizza lifescience

Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup · Rajkot, Gujarat, India

Registered address: Rajkot, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
Not shared
Employees
–
GST
24GQFPM5460R1Z4
IEC code
GQFPM5460R
Export markets
Algeria flag DZ Andorra flag AD Anguilla flag AI Angola flag AO Argentina flag AR +47 others
GlobalLinker Member Since
Aug 2025
Turnover
Incorporation Type
On request
Verified Seller
Product details

What are the specifications of this product?

Overview

Product Name: Fastograf 300 Injection Generic Name: Filgrastim 300 mcg Manufacturer: Cytomed Therapeutic Category: Oncology Supportive Care / Hematopoietic Growth Factor Product Description: Fastograf 300 Injection contains Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It is used to stimulate the bone marrow to produce more neutrophils (a type of white blood cell), helping reduce the risk of infection in patients receiving chemotherapy, bone marrow transplant, or suffering from neutropenia. Indications: • Chemotherapy-induced neutropenia • Bone marrow transplantation • Severe chronic neutropenia (SCN) • Mobilization of peripheral blood progenitor cells (PBPC)

Product Description

Mechanism of Action:

Filgrastim binds to specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, and activation of neutrophil precursors.

This leads to faster recovery of neutrophil counts and improved infection defense.


Dosage & Administration:

• Administered as subcutaneous (SC) injection or intravenous (IV) infusion.

• Dose depends on indication, body weight, and clinical condition.

• Treatment duration continues until the desired neutrophil count is achieved.

(To be given under oncologist/hematologist supervision.)


Key Benefits:

• Reduces duration and severity of chemotherapy-induced neutropenia.

• Lowers risk of life-threatening infections.

• Improves treatment continuity for cancer patients.


Packaging:

• Prefilled syringe / Vial containing 300 mcg/0.5 mL.


Storage:

• Store at 2°C – 8°C (Refrigerated).

• Do not freeze or shake.

• Protect from light.


Important Notes:

• For hospital/oncology use under strict medical supervision only.

• Side effects may include bone pain, injection site reactions, mild fever.

• Regular monitoring of complete blood counts (CBC) is essential during therapy.


Melizza Lifescience

Oncology supplier

Description provided by melizza lifescience.

Specifications

Generic Name Filgrastim
Dosage Strength 300 mcg per 0.5 mL
Formulation Injection
Intended Use Support bone marrow recovery and neutrophil count increase
Side Effects Bone pain, injection site reactions, mild fever
Shelf Life As per manufacturer guidelines; store refrigerated
Handling Precautions Avoid freezing and shaking, protect from direct light exposure
Route of Administration Subcutaneous (SC) or Intravenous (IV)
Treatment Duration Until desired neutrophil count is achieved, varies by patient condition
Monitoring Requirements Complete blood counts (CBC) regularly during therapy

Use cases

Category Pharmaceuticals > Oncology Supportive Care > Hematopoietic Growth Factors
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition As recommended by supplier
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Centimetre
Lead time On request
Payment terms As per negotiated commercial agreement.
Checkout type enquiry
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing FASTOGRAF 300 INJ. Answers compiled from verified sellers' commercial terms and platform data.

Q: What differentiates Fastograf 300 Injection from other Filgrastim products in chemotherapy support?
A: Fastograf 300 Injection offers a precisely measured 300 mcg dose in a 0.5 mL prefilled syringe or vial, ensuring accurate administration. Manufactured by Cytomed Therapeutics, it is specifically formulated for oncology supportive care with strict refrigeration and handling standards, providing reliable neutrophil recovery and infection risk reduction.
Q: Can Fastograf 300 Injection be used for mobilization of peripheral blood progenitor cells (PBPC)?
A: Yes, Fastograf 300 Injection is indicated for the mobilization of peripheral blood progenitor cells, facilitating their collection for transplantation purposes.
Q: What are the storage requirements critical for maintaining Fastograf 300 Injection efficacy?
A: Fastograf 300 Injection must be stored refrigerated between 2°C to 8°C, must not be frozen or shaken, and should be protected from light to maintain its potency and safety.
Q: What monitoring protocols should be followed during Fastograf 300 Injection therapy?
A: Regular monitoring of complete blood counts (CBC) is essential during therapy with Fastograf 300 to track neutrophil levels and adjust treatment duration accordingly under oncologist supervision.
Q: Is Fastograf 300 Injection suitable for outpatient administration?
A: Fastograf 300 Injection is intended for hospital or oncology center use only, requiring administration under strict medical supervision due to its specialized dosage and monitoring requirements.
Question not answered? Ask sellers directly — typical response within 4 hours.

What similar products are available in this category?

Browse all in category
View all →
syringe glycerine
syringe glycerine
Price on request MOQ 1 Centimetre
View Product
guaze swab
guaze swab
Price on request MOQ 1 Centimetre
View Product
cannula fixrator
cannula fixrator
Price on request MOQ 1 Centimetre
View Product
disposable underpad
disposable underpad
Price on request MOQ 1 Unit
View Product
abgel sponge pad
abgel sponge pad
Price on request MOQ 1 Unit
View Product
examination gloves
examination gloves
$ 4.52 MOQ 1 Unit
View Product
remtrex 2.5mg, 15mg,
remtrex 2.5mg, 15mg,
Price on request MOQ 1 Centimetre
View Product
capeta nova 500mg
capeta nova 500mg
Price on request MOQ 1 Centimetre
View Product
FASTOGRAF 300 INJ
FASTOGRAF 300 INJ
Price on request · MOQ 1Centimetre